A method is provided for reducing a risk that a subject will experience a medically-related adverse event associated with inappropriate consumption of alcohol concurrent with the taking of a nonbenzodiazepine benzodiazepine receptor agonist (NBBRA). In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more NBBRAs, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the NBBRA in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing the risk of the subject experiencing an alcohol-induced medically-related adverse event. Also disclosed are the combination products that include the effective amount of one or more NBBRAs and the effective amount of one or more ALDIs.

A method is provided for reducing a risk that a subject will experience a medically-related adverse event associated with inappropriate consumption of alcohol concurrent with the taking of a nonbenzodiazepine benzodiazepine receptor agonist (NBBRA). In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more NBBRAs, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the NBBRA in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing the risk of the subject experiencing an alcohol-induced medically-related adverse event. Also disclosed are the combination products that include the effective amount of one or more NBBRAs and the effective amount of one or more ALDIs.

The present invention relates to the reduction of stress in ruminants in need thereof.

The present invention relates to the reduction of stress in ruminants in need thereof.

A method of treating postprandial inflammation, or inhibiting an inflammatory response in a subject, may include administering to a subject an edible composition comprising an ACSL1 inhibitor. The ACSL1 inhibitor may be administered before or during consumption of a food high in fat, particularly a food high in saturated fat. The ACSL1 inhibitor may prevent a pro-inflammatory response, weight gain, or the development or progression of a disease associated with the consumption of high fat foods, such as dyslipidemia, obesity, diabetes, arthritis, or hepatic steatosis.

A method of treating postprandial inflammation, or inhibiting an inflammatory response in a subject, may include administering to a subject an edible composition comprising an ACSL1 inhibitor. The ACSL1 inhibitor may be administered before or during consumption of a food high in fat, particularly a food high in saturated fat. The ACSL1 inhibitor may prevent a pro-inflammatory response, weight gain, or the development or progression of a disease associated with the consumption of high fat foods, such as dyslipidemia, obesity, diabetes, arthritis, or hepatic steatosis.

A method and device can alternately deliver high concentration of nitric oxide and oxygen-enriched air.

A method and device can alternately deliver high concentration of nitric oxide and oxygen-enriched air.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT.sub.1D, 5-HT.sub.2A, 5-HT.sub.2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose.